Myriad Genetics (NASDAQ:MYGN) Stock Rating Upgraded by The Goldman Sachs Group
The Goldman Sachs Group upgraded shares of Myriad Genetics (NASDAQ:MYGN – Get Rating) from a sell rating to a buy rating in a research note published on Tuesday morning, The Fly reports. The firm currently has $25.00 target price on the stock, up from their previous target price of $18.00. Other research analysts have also […]